biolog
inhibitor
significantli
improv
clinic
outcom
mani
autoimmun
diseas
particular
rheumatoid
arthriti
howev
practic
use
limit
due
high
cost
risk
antidrug
antibodi
respons
attempt
develop
vaccin
gener
encourag
data
anim
model
howev
data
clinic
trial
met
expect
present
studi
design
epitopescaffold
immunogen
use
transmembran
domain
diphtheria
toxin
name
dtt
scaffold
molecular
dynam
simul
show
graft
epitop
entir
surfaceexpos
present
nativelik
conform
rigid
helic
structur
dtt
minim
perturb
therebi
render
immunogen
highli
stabl
immun
mice
alum
formul
induc
humor
respons
nativ
antibodi
titer
sustain
month
support
role
univers
cell
epitop
dtt
break
selfimmun
toler
mous
model
rheumatoid
arthriti
vaccin
markedli
delay
onset
collageninduc
arthriti
reduc
incid
well
clinic
score
dtt
presum
safe
epitop
carrier
catalyt
inact
mutant
diphtheria
toxin
good
clinic
safeti
record
activ
vaccin
compon
taken
togeth
show
dttbase
epitop
vaccin
promis
strategi
prevent
treatment
autoimmun
diseas
plan
develop
optim
version
therapeut
vaccin
alter
author
adher
plo
one
polici
share
data
materi
fig
stabil
dtt
dtnf
protein
thermal
stabil
dtt
dtnf
protein
measur
dsc
left
panel
temperatur
depend
heat
capac
dtt
dtnf
protein
right
panel
melt
temperatur
dtt
dtnf
protein
b
sdspage
analysi
solubl
fraction
dtt
dtnf
protein
store
day
top
day
bottom
conceptu
lz
azx
rxl
formal
analysi
jw
fund
acquisit
rxl
investig
lz
jw
chz
methodolog
lz
jw
azx
chz
pleiotrop
proinflammatori
cytokin
play
pivot
role
physiolog
patholog
process
primari
function
regul
immun
cell
inflamm
well
protect
immun
respons
varieti
infecti
pathogen
master
regul
proinflammatori
cytokin
gmcsf
express
caus
varieti
chronic
inflammatori
diseas
includ
rheumatoid
arthriti
crohn
diseas
psoriat
arthriti
ankylos
spondyl
psoriasi
blockad
activ
monoclon
antibodi
eg
infliximab
adalimumab
well
receptorimmunoglobulin
fusion
protein
eg
etanercept
significantli
improv
clinic
outcom
particular
rheumatoid
arthriti
nevertheless
biolog
inhibitor
approv
clinic
use
limit
practic
due
high
manufactur
cost
risk
antidrug
antibodi
ada
respons
therefor
imper
develop
novel
strategi
circumv
shortcom
activ
immun
intens
investig
altern
approach
address
limit
far
vaccin
base
whole
molecul
tnfk
tnf
autovaccin
shown
remark
result
anim
studi
howev
vaccin
strategi
success
human
trial
tnfk
conjug
mixtur
klh
bioactiv
cytokin
inactiv
formaldehyd
treatment
tnf
autovaccin
compris
two
recombin
protein
specif
peptid
replac
cell
epitop
tetanu
toxin
case
elicit
antibodi
respons
endogen
molecul
weak
humor
respons
immunogen
partial
denatur
strong
suggest
epitop
compromis
product
process
thu
ration
design
necessari
gener
stabl
structur
feasibl
manufactur
sinc
potent
cytokin
whole
molecul
immunogen
need
inactiv
either
chemic
modif
formaldehyd
treatment
site
direct
mutagenesi
howev
approach
unavoid
compromis
immunogen
immunogen
therefor
peptid
epitop
base
vaccin
design
prefer
choic
work
capini
et
al
shown
cyclic
epitop
peptid
aa
conjug
klh
elicit
stronger
neutral
antibodi
respons
linear
counterpart
suggest
stabil
conform
peptid
epitop
key
criterion
vaccin
design
develop
epitopescaffold
immunogen
conform
epitop
peptid
aa
stabil
transplant
onto
scaffold
molecul
transmembran
domain
diphtheria
toxin
dtt
assess
immunogen
vaccin
nativ
mice
well
therapeut
efficaci
collageninduc
arthriti
mous
model
result
show
dttbase
epitopescaffold
vaccin
promis
strategi
prevent
treatment
autoimmun
diseas
immun
use
balbc
mice
femal
age
mice
per
experiment
group
vaccin
efficaci
cia
mous
model
use
mice
male
age
week
mice
group
mice
dtt
control
group
mice
purchas
slac
laboratori
anim
centr
shanghai
china
kept
specif
pathogenfre
condit
shanghai
jiao
tong
univers
anim
center
anim
studi
perform
accord
institut
guidelin
approv
institut
anim
care
use
committe
shanghai
jiao
tong
univers
euthanasia
carri
use
co
accord
american
veterinari
medic
associ
guidelin
mice
inspect
dailybasi
sign
ill
health
distress
euthan
anim
end
experi
sinc
mice
reach
human
endpoint
includ
weight
loss
sever
lame
dyspnea
ruffl
fur
weak
dehydr
hunch
appear
blister
inject
site
variou
number
amino
acid
residu
posit
diphtheria
toxin
tdomain
dtt
aa
dt
correspond
aa
dt
replac
epitop
use
discoveri
studio
result
epitopescaffold
protein
denot
dtnf
protein
name
amino
acid
residu
correspond
dtt
aa
aa
aa
aa
aa
aa
replac
epitop
vsrfaisyqekvnl
aa
respect
aa
replac
epitop
vsrfaisyqekvnl
av
aa
inter
residu
distanc
td
dd
calcul
swisspdb
viewer
base
xray
crystal
structur
mous
diphtheria
toxin
pdb
entri
td
stand
interatom
distanc
valin
serin
valin
dd
stand
interatom
distanc
end
residu
replac
segment
interatom
distanc
calcul
use
coordin
nitrogen
atom
alphaamino
group
ntermin
end
residu
carbon
atom
alphacarboxi
group
ctermin
end
residu
protein
express
purifi
homogen
accord
hatem
elshabrawi
dna
encod
dtnf
presciss
proteas
cleavag
site
gener
overlap
pcr
digest
bamhi
xhoi
clone
vector
dna
transform
cell
protein
express
induc
iptg
isopropyldthiogalactopyranosid
cultur
reach
od
cultur
addit
h
cell
pellet
centrifug
resuspend
pb
sonic
debri
remov
centrifug
supernat
appli
gstcolumn
ge
healthcar
accord
manufactur
instruct
gst
tag
cleav
presciss
proteas
overnight
remov
gst
affin
column
result
dtnf
protein
purifi
superdex
chromatographi
immunogen
dtnf
protein
purifi
dtt
dtnf
protein
mix
aluminum
hydroxid
adjuv
invivogen
inject
femal
balbc
mice
week
old
intraderm
follow
three
boost
inject
protein
plu
aluminum
hydroxid
adjuv
blood
sampl
draw
retroorbit
sinu
punctur
anesthesia
isofluran
inhal
day
antidtt
ab
titer
igg
subclass
measur
elisa
differenti
scan
calorimetri
dsc
mgml
dtnf
protein
degass
protein
unfold
event
record
vpcapillari
differenti
scan
calorimet
microc
llc
scan
rate
min
constant
pressur
psi
data
analyz
use
origin
accord
manufactur
instruct
cd
spectra
nm
record
jasco
quartz
cell
protein
concentr
mgml
tertiari
structur
dtnf
protein
model
base
xray
crystal
structur
dt
mous
mention
valid
procheck
md
simul
perform
previous
describ
use
desmond
default
set
last
ns
protein
structur
visual
use
pymol
softwar
cia
induc
arthriti
score
assess
accord
wei
tang
briefli
mgml
chicken
type
ii
collagen
chondrex
mix
equal
volum
cfa
mycobacterium
tuberculosi
tissu
homogen
day
sixweekold
mice
anesthet
isofluran
inhal
accord
iacuc
inject
intraderm
result
emuls
base
tail
day
experiment
group
mice
inject
intraderm
formul
alum
control
group
mice
inject
alum
dtt
day
mice
boost
immunogen
formul
alum
mice
monitor
daili
basi
arthriti
incid
evalu
two
three
time
per
week
sever
paw
score
use
score
system
paw
score
sum
yield
individu
mous
score
maximum
score
mous
score
normal
mild
swell
confin
tarsal
bone
ankl
joint
mild
swell
extend
ankl
tarsal
bone
moder
swell
extend
ankl
metatars
joint
sever
swell
encompass
ankl
foot
digit
ankylosi
limb
histolog
analysi
hematoxylineosin
stain
safranin
stain
mice
sacrif
day
hind
paw
use
sera
dilut
concentr
cytokin
measur
use
luminex
multiplex
technolog
biorad
laboratori
accord
manufactur
instruct
mean
sem
mean
se
calcul
prism
graphpad
three
ten
replic
statist
comparison
perform
use
ttest
p
p
p
consid
signific
molecular
design
epitopescaffold
immunogen
nagahira
k
et
al
shown
neutral
monoclon
antibodi
bind
posit
conjug
klh
linear
epitop
peptid
aa
elicit
weak
antibodi
respons
nativ
wherea
cyclic
form
induc
stronger
antibodi
respons
indic
stabl
conform
prefer
immunogen
crystal
structur
mous
pdb
residu
form
structur
fig
interatom
distanc
end
residu
search
scaffold
epitop
found
diphtheria
toxin
tdomain
dtt
aa
dt
could
good
candid
conform
stabil
adjuv
firstli
function
tdomain
engag
transloc
catalyt
domain
dt
across
endosom
membran
low
phdepend
manner
thu
safeti
issu
associ
domain
secondli
dtt
rigid
tertiari
structur
compos
entir
loop
fig
therefor
potenti
toler
transplant
foreign
peptid
render
peptid
stabl
conform
moreov
dtt
express
ecoli
highli
solubl
protein
cd
spectrum
purifi
dtt
show
typic
helic
conform
two
minima
fig
would
substanti
reduc
manufactur
cost
thirdli
dtt
possess
four
help
cell
epitop
aa
correspond
dt
aa
recogn
human
major
histocompat
complex
hal
popul
coverag
respect
human
mhc
ii
gene
highli
polymorph
combin
univers
th
epitop
promis
popul
coverag
among
peopl
previous
immun
dt
vaccin
th
epitop
dttbase
vaccin
induc
rapid
recal
respons
memori
cell
shown
fig
dtt
residu
posit
form
turnhelixturn
structur
entir
surfaceexpos
specul
potenti
site
epitop
transplant
sinc
interatom
distanc
end
residu
epitop
peptid
shorter
dtt
aa
direct
transplant
would
potenti
introduc
conform
constraint
dtt
epitop
order
identifi
appropri
transplant
keep
epitop
conform
close
nativ
molecul
dtt
conform
minim
perturb
gener
seven
epitopescaffold
molecul
fig
differ
interatom
distanc
epitop
replac
segment
vari
rang
close
replac
residu
turn
helix
choos
experi
gener
replac
dtt
epitop
peptid
encompass
residu
inclus
one
residu
epitop
peptid
increas
td
reduc
dtnf
protein
express
e
coli
purifi
homogen
highli
solubl
concentr
greater
mgml
pb
ph
circular
dichroism
spectra
characterist
conform
similar
dtt
fig
fig
show
mice
immun
individu
dtnf
protein
gener
high
titer
antibodi
dtt
fig
indic
transplant
interfer
antigen
dtt
howev
elicit
robust
antibodi
respons
mous
human
wherea
rest
dtnf
protein
induc
much
weaker
respons
fig
fig
indic
epitop
present
perturb
immunogen
antibodi
respons
nativ
observ
mice
immun
dttpeptid
conjug
dtnf
consist
previou
report
show
peptid
linear
form
conjug
klh
poor
immunogen
immun
mice
antibodi
day
subclass
fig
suggest
immunoglobulin
class
switch
complet
immun
respons
domin
type
helper
cell
remark
titer
sustain
six
month
level
decreas
slightli
maximum
respons
day
fig
suggest
b
cell
respons
mediat
activ
helper
cell
comparison
conjug
vaccin
target
transient
antibodi
respons
observ
due
lack
thdepend
b
cell
respons
data
demonstr
univers
th
epitop
dtt
help
overcom
shortcom
sustain
antibodi
respons
benefici
treatment
rheumatoid
arthriti
excess
persist
express
patient
mice
immun
grew
normal
bodi
weight
size
liver
spleen
skin
morpholog
show
differ
control
mice
administ
pb
dtt
red
inject
site
observ
immun
mice
data
implic
vaccin
formul
safe
studi
warrant
exam
whether
vaccin
perturb
physiolog
function
cytokin
signific
thereof
sinc
valu
greater
weaker
antibodi
respons
would
indic
conform
constraint
caus
transplant
affect
immunogen
epitop
howev
weaker
respons
explain
conform
constraint
valu
lower
shown
induct
robust
antibodi
respons
highli
correl
conform
stabil
immunogen
therefor
failur
induc
antibodi
respons
may
due
overal
conform
stabil
test
possibl
perform
dsc
look
thermal
stabil
dtnf
protein
dtt
shown
fig
tm
valu
dtnf
protein
lower
dtt
unstabl
protein
tm
dtt
tm
valu
decreas
decreas
sinc
tm
valu
slightli
higher
poor
immunogen
explain
thermal
stabil
find
whether
stabil
secondari
structur
element
could
account
immunogen
dtnf
protein
perform
molecular
dynam
simul
fig
show
conform
epitop
dtnf
protein
stabl
close
except
whose
ser
adopt
coil
conform
instead
extend
conform
shown
fig
epitop
entir
surfac
expos
contrast
conform
stabil
scaffold
perturb
variou
degre
dtnf
protein
least
affect
helix
dtt
posit
stabl
fig
particularli
helix
highli
flexibl
rmsf
abruptli
increas
compar
dtt
fig
residu
posit
also
display
higher
degre
flexibl
secondari
structur
stabl
epitop
conform
close
howev
rmsf
posit
decreas
compar
dtt
indic
constrain
conform
scaffold
unfavor
epitop
present
fig
consist
observ
solubl
recombin
protein
vari
storag
day
pb
solut
especi
unstabl
becom
complet
insolubl
storag
fig
investig
therapeut
efficaci
immun
mice
purifi
protein
collagen
administr
use
dtt
control
fig
compar
dtt
treat
mice
vaccin
delay
onset
arthriti
day
reduc
arthriti
incid
rate
fig
markedli
decreas
clinic
arthriti
score
fold
fig
shown
fig
symptom
includ
joint
swell
erythema
significantli
improv
consist
histolog
examin
hind
paw
demonstr
vaccin
reduc
synovi
inflamm
cartilag
destruct
bone
eros
immun
cell
infiltr
fig
bodi
weight
mice
immun
similar
immun
dtt
fig
moreov
serum
level
proinflammatori
cytokin
persist
rheumatoid
arthriti
includ
interleukin
decreas
although
level
chang
reach
statist
signific
fig
note
level
increas
vaccin
consist
passiv
immun
antibodi
level
downregul
administr
epitop
peptidebas
vaccin
activ
explor
vaccin
design
virtu
target
specif
potenti
avoid
allergen
andor
reactogen
effect
associ
vaccin
use
whole
organ
larg
protein
howev
epitop
peptid
inher
poor
immunogen
one
challeng
vaccin
design
identifi
appropri
safe
carrier
scaffold
structuralchem
stabil
adjuv
far
epitopepeptid
vaccin
reach
commerci
market
yet
due
lack
efficaci
andor
safeti
concern
studi
demonstr
dtt
serv
carrier
scaffold
vaccin
design
target
selfmolecul
includ
show
transplant
neutral
epitop
dtt
posit
stabil
epitop
nativelik
conform
scaffold
conform
minim
perturb
univers
th
epitop
dtt
facilit
helper
celldepend
b
cell
activ
critic
longlast
humor
respons
sinc
epitop
peptid
sequenc
highli
homolog
mous
human
transplant
strategi
could
directli
appli
human
vaccin
design
data
also
suggest
success
vaccin
design
use
dtt
avoid
introduct
larg
conform
constrain
scaffold
peptid
epitop
addit
stabl
secondari
structur
transplant
peptid
prefer
transplant
segment
dtt
flexibl
loop
flexibl
peptid
epitop
could
achiev
engin
disulfid
bond
epitop
peptid
length
peptid
optim
keep
span
differ
minimum
solubl
purifi
molecul
storag
pb
good
indic
overal
stabil
b
fragment
dt
dtb
compos
tdomain
receptor
bind
rdomain
shown
effect
vaccin
carrier
howev
dtt
better
dtb
regard
antigen
load
dtt
possess
one
b
cell
epitop
wherea
dtb
contain
sever
highli
immunogen
b
cell
epitop
r
domain
b
cell
epitop
dt
shown
suppress
immun
respons
certain
conjug
hapten
compet
dt
prime
helper
cell
case
happen
dttbase
vaccin
appropri
mutat
may
introduc
modifi
elimin
b
cell
epitop
dtt
collageninduc
arthriti
cia
commonli
use
anim
model
human
rheumatoid
arthriti
chronic
inflammatori
autoimmun
diseas
attack
joint
far
immunogen
shown
phylact
effect
cia
mous
model
first
vaccin
show
therapeut
effect
collagen
immun
onset
arthriti
plasma
level
extraordinarili
high
cia
model
mice
pgml
compar
transgen
mice
pgml
consequ
unabl
determin
whether
antibodi
elicit
immun
could
neutral
bioactiv
assay
use
dilut
sera
measur
plasma
level
cytokin
downstream
day
less
compar
dtt
immun
cia
mice
therefor
detail
time
cours
cytokin
level
would
reveal
insight
cia
model
therapeut
mechan
immun
almost
known
cytokin
present
ra
synovi
fluid
among
first
cytokin
prove
effect
therapeut
target
recent
year
immuneregulatori
function
gmcsf
shown
play
crucial
role
drive
develop
mani
autoimmun
diseas
gmcsf
receptortarget
therapi
shown
highli
effect
remark
safe
treatment
mani
autoimmun
diseas
particular
ra
note
antigenspecif
regulatori
cell
activ
therapeut
antagon
gmcsf
shown
play
major
immun
suppress
role
ra
autoimmun
diseas
mechan
also
underli
immun
toler
acaid
anterior
chamber
associ
immun
deviat
studi
shukkur
farooq
show
collagen
type
iispecif
acaid
treg
suppress
inflamm
cia
therefor
await
investig
determin
whether
immun
modul
function
collagenspecif
treg
cia
whether
treg
cell
function
equival
acaid
treg
